Scope and Claims Analysis of US Patent 7,157,466 (Formula II Compounds, Hydrates/Anhydrates, XRPD-Defined Solids, and Pharmaceutical Compositions)
US 7,157,466 is a US patent centered on a defined chemical “compound of Formula (II)” plus solid-state forms (anhydrate, monohydrate, and mixtures) and downstream protection for pharmaceutical compositions containing those forms. The claim set uses two layers of coverage: (1) broad structural/identity coverage for “compounds of Formula (II) and hydrate/anhydrate forms,” then (2) narrower solid-form and crystallinity coverage via powder X-ray diffraction (XRPD) peak lists that function as objective identity limitations. It also covers formulation/composition claims that are structurally simple, relying on the “therapeutically effective amount” of the claimed solid-form(s) and standard excipients.
What does US 7,157,466 claim in plain terms?
Core protected subject matter (claims 1–6):
- A chemical entity defined by Formula (II), including anhydrate and hydrate forms.
- The same compound/solid forms, further limited by XRPD peak-pattern definitions (claims 2 and 3), using specified “Two theta” and “d-spacing” peak lists.
- Separate explicit coverage for:
- anhydrate form (claim 4)
- monohydrate form (claim 5)
- a mixture of anhydrous and hydrate forms (claim 6)
Downstream protected subject matter (claims 7–10):
- Pharmaceutical compositions containing a therapeutically effective amount of:
- the compound of claim 1 (claim 7)
- the anhydrate-only form (claim 8)
- the monohydrate-only form (claim 9)
- the mixture of forms (claim 10)
- Each composition claim adds standard “pharmaceutically acceptable carriers, diluents and excipients,” with the “carrier list” functioning as conventional formulation coverage without adding a specific route of administration, dosage form, or drug-product technology.
How broad are the claim 1–10 coverage boundaries?
Claim 1 creates the broad structural “anchor.” It covers:
- The “compound of Formula (II)” itself (implicit identity)
- Plus “anhydrate or hydrate forms thereof” (solid-state variants)
This is broader than the XRPD-limited claims because it does not require the solid-form to match a specific diffraction fingerprint; it requires only that the material is an anhydrate or hydrate of the Formula (II) compound.
Claims 2 and 3 are identity-limited by XRPD peak lists. These narrow claims can capture specific crystallographic forms or specific preparations that reproduce the listed peaks. XRPD peak-pattern claims typically handle common defenses by using measurable structural signatures, but they still depend on:
- measurement conditions (instrument calibration, beam settings, sample prep, humidity history, particle size)
- peak thresholding and whether extra peaks appear in the pattern
Claims 4–6 split solid-state coverage by physical form category:
- “anhydrate form”
- “monohydrate form”
- “mixture of anhydrous and hydrate forms”
These are typically interpreted as covering all materials that fall into those categories, even if their XRPD patterns do not exactly match claims 2 or 3, depending on claim construction and specification support for what “anhydrate” and “monohydrate” mean in the patent.
Claims 7–10 cover standard compositions without specifying dosage form.
They are formulation claims that usually read on:
- oral tablets/capsules
- powders
- granules
- potentially inhalation formulations
only if those are “pharmaceutical composition” formats contemplated and supported, but the claim language itself does not restrict to a particular dosage form, route, or release mechanism.
What is the scope of the XRPD peak-pattern limitations in claims 2 and 3?
The XRPD limitations add objective constraints by requiring the powder X-ray diffraction pattern to comprise specified peak positions. The claims use the following peak listings.
Claim 2 XRPD peak list (as written)
Two theta (deg) and d-spacing (angstroms) pairs:
- 4.8 deg → 18.0 Å
- 8.7 deg → 10.18 Å
- 8.9 deg → 10.?? Å (note: the user-provided text appears to contain a formatting ambiguity around 18.9/4.7 and 21.0/4.2; the operative limitation is the set of provided pairs)
- 18.0? deg → 4.9 Å
- 18.9? deg → 4.7 Å
- 21.0? deg → 4.2 Å
- 22.3? deg → 4.0 Å
Claim 3 XRPD peak list (as written)
Pairs:
- 6.6 deg → 13.0 Å
- 8.3 deg → 10.11 Å
- 11.5 deg → 7.7 Å
- 18.1 deg → 4.9 Å
- 21.1 deg → 4.2 Å
Practical claim construction impact: XRPD claims are often litigated on whether the accused material’s diffraction pattern includes the claimed “comprising the peaks” set. The “comprising” phrasing typically means the pattern may include additional peaks beyond those listed, but must still include those listed peaks at comparable positions under the claim’s measurement paradigm.
How do claims 4–6 relate to claims 2–3 (anhydrate/monohydrate vs XRPD-defined forms)?
- Claims 4 and 5 define solid-state form categories by hydration state (anhydrate vs monohydrate).
- Claims 2 and 3 define solid-state identity by XRPD pattern features.
Those can overlap:
- A monohydrate can be expected to have a characteristic XRPD pattern that matches a claim 2 or 3 pattern, if the specification aligns those patterns with the hydration form.
- A hydration-state category can be broader than a specific XRPD fingerprint if multiple polymorphs or variants exist for the same hydration state, or if peak positions shift with sample history and conditions.
From a freedom-to-operate perspective, the existence of both XRPD and hydration-state claims increases risk: avoiding claim 2 and 3 by using an “alternative crystal form” may not avoid claims 4–6 if the alternative material still qualifies as “anhydrate” or “monohydrate.”
What patent landscape features does this claim architecture suggest?
Given the claims’ structure, US 7,157,466 is likely positioned as:
- A solid-form patent (anhydrate/monohydrate and mixtures) protecting physical forms and solid-state-defined variants, plus
- A composition patent protecting the formulation of those forms.
That usually places the estate in the middle of a typical patent strategy for poorly compressible or stability-sensitive drug substances, where later filings often attempt to capture:
- additional polymorphs
- amorphous forms
- particle size distributions
- cocrystal/salt forms
- process-defined solid forms
- specific dosage forms or stabilization approaches
However, without the drug identity (name, INN, salt form, and the specification’s definition of Formula II) and without the patent’s written description content, a complete landscape cannot be reconstructed with hard data.
How would this patent be used in litigation risk terms?
1) Infringement pathways for a generic or follow-on product
A generic competitor attempting to market a drug substance that corresponds to Formula (II) would face infringement risk if it uses:
- the same compound in anhydrate/monohydrate/mixture forms covered by claims 1 and 4–6
- a solid form whose XRPD pattern includes the claimed peaks in claims 2–3
- a finished pharmaceutical composition that includes the claimed form in a therapeutically effective amount (claims 7–10)
2) Common defenses likely to be raised against XRPD peak claims
- XRPD pattern does not “comprise” the claimed peak set under relevant test conditions.
- The accused material is not an “anhydrate” or “monohydrate” within the patent’s definition (or is a different hydrate stoichiometry).
- The accused product does not include the claimed solid state (for example, it uses an amorphous form or different polymorph).
Because claims 1 and 4–6 do not require XRPD, defeating the XRPD claims alone may not avoid infringement if the hydration state category still matches.
What specific claim elements create the strongest enforcement leverage?
- “Compound of Formula (II)”: establishes chemical identity coverage. If Formula II corresponds to the active pharmaceutical ingredient (API), then any product containing that API in the covered solid state is within reach.
- Hydration-state claims (4–6): these can capture reformulations that keep the same hydration state but vary polymorph/crystallinity.
- XRPD peak lists (2–3): these convert solid-form characterization into measurable conditions that can be tested on accused samples.
- Composition claims (7–10): they avoid the need to prove end-user dosing mechanics. “Pharmaceutical composition” plus “therapeutically effective amount” plus standard excipients is usually enough to capture typical dosage forms.
What does this suggest about the breadth vs. validity balance?
- Breadth: Claim 1 is broad in terms of chemistry and solid-state class. Claims 7–10 are broad in terms of formulation since they do not specify excipient types, dosage form, or route.
- Narrowing: Claims 2 and 3 narrow solid-form identity using XRPD peaks.
- Balance: The combination of broad base claims (1, 4–6, 7–10) with narrower XRPD claims supports an argument that the patentee has a clear technical basis for at least some embodiments, while still claiming broadly.
The central validity question in such estates usually involves:
- enablement and written description of the full scope of “anhydrate” and “monohydrate”
- whether the XRPD patterns are sufficiently described and reproducible
- whether “mixture of anhydrous and hydrate forms” is defined with enough specificity to avoid indefiniteness
But those require the patent’s full text and prosecution history, which are not provided.
Key takeaways
- US 7,157,466 protects Formula (II) compounds in anhydrate and hydrate forms, with separate solid-form claims for anhydrate, monohydrate, and a mixture.
- The patent adds XRPD-defined sub-coverage in claims 2 and 3 using specific powder diffraction peak lists.
- It also protects pharmaceutical compositions that include therapeutically effective amounts of those covered solids, without restricting dosage form or excipient type beyond “pharmaceutically acceptable” language.
- Litigation and generic risk likely hinge on whether an accused product uses the same hydration-state category and, if contested, whether its XRPD pattern includes the listed peaks.
FAQs
- Do claims 2 and 3 require the XRPD pattern to match exactly, or just contain listed peaks?
- If a competitor avoids the XRPD peak lists, can it still infringe claims 4–6 as an anhydrate/monohydrate?
- Do claims 7–10 cover specific dosage forms like tablets or capsules, or only any “pharmaceutical composition”?
- How does a “mixture of anhydrous and hydrate forms” differ from a pure monohydrate in infringement analysis?
- What sample-prep and testing-condition issues most affect XRPD peak-based infringement disputes?
References
- US Patent 7,157,466.
